18 and older, any sex, with Glaucoma, Open-Angle or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Intraocular Pressure (IOP)Primary· 12 weeks
Percent Change from Baseline IOP at Week 12, as measured by Goldmann applanation tonometry.
Prostaglandin analog (PGA). Fixed dose combination (FDC).
Group
Value
95% CI
Netarsudil Ophth Sol 0.02% Monotherapy - Tx Naïve At Baseline
-16.9
± 16.35
Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 1 Agent
-2.3
± 16.23
Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 2 Agents
0.2
± 8.81
Netarsudil Ophth Sol 0.02% Concomitant Therapy
-17.0
± 16.81
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data was collected during the course of the 12-week treatment period..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular hypertension in a real-world clinical setting. The study is an open-label design. The patients will receive treatment for 12 weeks.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
Other trials of Netarsudil Ophthalmic Solution 0.02%
Trials testing the same drug.
NCT03844945 — Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma
· Phase 2
· completed
NCT03233308 — Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
· Phase 2
· completed
Other recruiting trials for Glaucoma, Open-Angle
Currently open trials in the same condition.
NCT06964191 — Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
· Phase 2
· recruiting
NCT06240312 — Optic Nerve Head Strain as Biomarker for Glaucoma
· NA
· recruiting
NCT05405868 — Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial
· Phase 3
· recruiting
NCT05710198 — Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
· Phase 3
· recruiting
NCT06058598 — Exercise Training in Patients With Glaucoma
· NA
· active not recruiting
Other Aerie Pharmaceuticals trials
Trials by the same sponsor.
NCT05493111 — A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512
· Phase 3
· completed
NCT05360966 — Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)
· Phase 3
· completed
NCT05285644 — Study Evaluating the Safety and Efficacy of AR-15512
· Phase 3
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aerie Pharmaceuticals
Last refreshed: 29 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03808688.